We have located links that may give you full text access.
Prognostic value of hyperuricemia in patients with acute coronary syndrome: A meta-analysis.
European Journal of Clinical Investigation 2019 January 31
BACKGROUND: The prognostic significance of elevated circulating uric acid level in patients with acute coronary syndrome (ACS) are conflicting. This meta-analysis aimed to assess the prognostic value of hyperuricemia in patients with ACS.
METHODS: A comprehensive literature search was performed in Pubmed, Embase, VIP, CNKI, and WanFang databases up to June 16, 2018. All observational studies that investigated the prognostic value of hyperuricemia in ACS patients were selected. Outcome of interests were major adverse cardiovascular events (MACEs), all-cause mortality or cardiovascular mortality.
RESULTS: A total of 9 studies enrolling 8,776 ACS patients were included and analyzed. ACS patients with hyperuricemia had an increased risk of MACEs (risk ratio [RR] 1.86; 95% confidence intervals [CI] 1.47-2.35), all-cause mortality (RR 1.86; 95%CI 1.49-2.32), and cardiovascular mortality (RR 1.74; 95%CI 1.36-2.22) after adjustment for the conventional risk factors. Stratified analysis showed that the prognostic significance of hyperuricemia was consistently observed in each subgroups.
CONCLUSIONS: This meta-analysis suggests that hyperuricemia independently predicts MACEs and death in ACS patients. Determination of uric acid level has potential to improve risk stratification of adverse outcomes in ACS patients. This article is protected by copyright. All rights reserved.
METHODS: A comprehensive literature search was performed in Pubmed, Embase, VIP, CNKI, and WanFang databases up to June 16, 2018. All observational studies that investigated the prognostic value of hyperuricemia in ACS patients were selected. Outcome of interests were major adverse cardiovascular events (MACEs), all-cause mortality or cardiovascular mortality.
RESULTS: A total of 9 studies enrolling 8,776 ACS patients were included and analyzed. ACS patients with hyperuricemia had an increased risk of MACEs (risk ratio [RR] 1.86; 95% confidence intervals [CI] 1.47-2.35), all-cause mortality (RR 1.86; 95%CI 1.49-2.32), and cardiovascular mortality (RR 1.74; 95%CI 1.36-2.22) after adjustment for the conventional risk factors. Stratified analysis showed that the prognostic significance of hyperuricemia was consistently observed in each subgroups.
CONCLUSIONS: This meta-analysis suggests that hyperuricemia independently predicts MACEs and death in ACS patients. Determination of uric acid level has potential to improve risk stratification of adverse outcomes in ACS patients. This article is protected by copyright. All rights reserved.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app